Altimmune to Participate at Two Upcoming Investor Conferences

ALT 11.26.2024

Full Press ReleaseSEC FilingsOur ALT Tweets

About Gravity Analytica

Recent News

  • 01.07.2025 - Annabel Samimy
  • 12.19.2024 - Altimmune Added to Nasdaq Biotechnology Index
  • 12.06.2024 - 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

Recent Filings

  • 01.03.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.11.2024 - 8-K Current report
PDF Version

GAITHERSBURG, Md.,Nov. 26, 2024(GLOBE NEWSWIRE) --Altimmune, Inc.(Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

  • AnnualEvercore HealthCONx Conference(Coral Gables, FL)Tuesday, December 3, 2024Fireside Chat at10:50 a.m. Eastern Time
  • Piper Sandler Annual Healthcare Conference(New York, NY)Wednesday, December 4, 2024Fireside Chat at3:30 p.m. Eastern Time

The sessions will be webcast and can be accessed by visiting theEventssection of the Altimmune website.

About AltimmuneAltimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visitwww.altimmune.com.

Follow @Altimmune, Inc. onLinkedInFollow @AltimmuneInc onTwitter

Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@altimmune.com

Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com

Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com

This press release was published by a CLEAR® Verified individual.

Primary Logo

Source: Altimmune, Inc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com